Related Experiment Video
Updated: Mar 13, 2026
05:41
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
3.5K
Microbiome, antibiotics and irritable bowel syndrome
1Department of Gastroenterology, Whittington Hospital, Magdala Avenue, London N19 5NF, UK.
British Medical Bulletin
|October 15, 2016
Summary
The gut microbiota plays a key role in irritable bowel syndrome (IBS). Modulating the gut microbiota, potentially with treatments like rifaximin, offers a promising therapeutic strategy for IBS symptom management.
Area of Science:
- Gastroenterology
- Microbiology
- Pharmacology
Background:
- Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder.
- The gut microbiota is increasingly implicated in IBS pathogenesis.
- Microbiota modulation is an emerging therapeutic strategy for IBS.
Purpose of the Study:
- To review the current evidence on the role of the gut microbiota in IBS.
- To discuss the efficacy of rifaximin in IBS treatment.
- To identify areas for future research in IBS and gut microbiota.
Main Methods:
- Selective literature searches were performed on PubMed and Google Scholar.
- Original and review articles were included.
- Evidence from animal and human studies was considered.
Main Results:
- Evidence supports the role of gut microbiota in IBS.
- Randomized controlled trials show rifaximin efficacy in reducing IBS symptoms.
- Inconsistencies in microbiota studies and the exact mechanism of rifaximin require further investigation.
Conclusions:
- Gut microbiota modulation is a potential therapeutic avenue for IBS.
- Further research is needed to identify predictors of response to rifaximin and manage symptom recurrence.
- Longitudinal studies using high-throughput methods are crucial for identifying biomarkers and therapeutic targets.
More Related Videos
Related Concept Videos
01:17Irritable Bowel Syndrome I: Introduction
1.3K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.3K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
832
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
832
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
959
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
959
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
520
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
520
01:21Drugs for Treatment of Constipation-Predominant IBS
1.1K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.1K
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
998
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
998